Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson's disease: A meta-analysis

Neuroscience Letters

Volumn 636, Issue , 2017, Pages 190-195

  Xie, Yi ^a   Feng, Hongliang ^a   Peng, Sisi ^a   Xiao, Jinsong ^a   Zhang, Junjian ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Cognition; Correlations; Folate; Homocysteine; Parkinson's disease; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL PRACTICE; COGNITIVE DEFECT; COMPARATIVE STUDY; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; META ANALYSIS; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY CONTROL; SYSTEMATIC REVIEW; ADULT; AGED; BLOOD; COGNITION; COGNITION DISORDERS; DRUG EFFECTS; FEMALE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COGNITION; COGNITION DISORDERS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; TREATMENT OUTCOME; VITAMIN B 12;

EID: 85001103575     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2016.11.007     Document Type: Article

References (46)

1. [1] Bhatia, P., Singh, N., Homocysteine excess: delineating the possible mechanism of neurotoxicity and depression. Fundam. Clin. Pharmacol. 29:6 (2015), 522–528.
2. [2] Seshadri, S., Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease?. J. Alzheimers Dis. 9:August (4) (2006), 393–398.
3. [3] Jakubowski, H., Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 13:December (15) (1999), 2277–2283.
4. [4] White, A.R., Huang, X., Jobling, M.F., Barrow, C.J., Beyreuther, K., Masters, C.L., Bush, A.I., Cappai, R., Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J. Neurochem. 76:March (5) (2001), 1509–1520.
5. [5] Jacobsen, D.W., Homocysteine and vitamins in cardiovascular disease. Clin. Chem. 44:August (8) (1998), 1833–1843.
6. [6] Aarsland, D., Beyer, M.K., Kurz, M.W., Dementia in parkinson's disease. Curr. Opin. Neurol. 21:December (6) (2008), 676–682.
7. [7] Gazewood, J., Richards, D., Clebak, K., Parkinson disease: an update. Am. Fam. Phys. 87:4 (2013), 267–273 (February 15).
8. [8] Gorgone, G., Curro, M., Ferlazzo, N., Parisi, G., Parnetti, L., Belcastro, V., Tambasco, N., Rossi, A., Pisani, F., Calabresi, P., Ientile, P., Caccamoet, D., Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated parkinson's disease patients. Neuromol. Med. 14:March (1) (2012), 84–90.
9. [9] Nevrly, M., Kanovsky, P., Vranona, H., Langova, K., Hlustik, P., Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients. Parkinsonism Relat. Disord. 15:July (6) (2009), 477–478.
10. [10] Ha, S.W., Kim, J.M., Cho, J.S., Plasma homocysteine levels in idiopathic Parkinson's disease: role of idiopathic Parkinson's disease and levodopa treatment. Parkinsonism Relat. Disord. 13 (2007), S116–9.
11. [11] Seshadri, S., Beiser, A., Selhub, J., Jacques, P.F., Rosenberg, I.H., D'Agostino, R.B., Wilson, P.W.F., Wolf, P.A., Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346:7 (2002), 476–483.
12. [12] Gibb, W.R., Lees, A.J., The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 51:June (6) (1988), 745–752.
13. [13] Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, C.W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A.E., Halliday, G., Goetz, C.G., Gasser, T., Dubois, B., Chan, P., Bloem, B.R., Adler, C.H., Deuschl, G., MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30:OCtober (12) (2015), 1591–1601.
14. [14] Rostom A, Dube C, Cranney A, et al., Celiac Disease. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Sep. (Evidence Reports/Technology Assessments, No. 104.) Appendix D. Quality Assessment Forms. http://www.ncbi.nlm.nih.gov/books/NBK35156.
15. [15] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analysis. BMJ 327:7414 (2003), 557–560 (September 6).
16. [16] Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315:7109 (1997), 629–634 (September 13).
17. [17] Rodriguez-Oroz, M.C., Lage, P.M., Sanchez-Mut, J., Lamet, I., Pagonabarraga, J., Toledo, J.B., Garcia-Garcia, D., Clavero, P., Samaranch, L., Irurzun, C., Matsubara, J.M., Irigoien, J., Bescos, E., Kulisevsky, J., Perez-Tur, J., Obeso, J.A., Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging and genetic study. Mov. Dis. 24:10 (2009), 1437–1444 (July 30).
18. [18] Chen, W.W., Cheng, X., Zhang, X., Zhang, Q.S., Sun, H.Q., Huang, W.J., Xie, Z.Y., The expression features of serum cystatin C and homocysteine of Parkinson's disease with mild cognition dysfunction. Eur. Rev. Med. Pharmacol. Sci. 19:August (16) (2015), 2957–2963.
19. [19] Zoccolella, S., Aquila, C.D., Abruzzese, G., Antonini, A., Bonuccelli, U., Canesi, M., Cristina, S., Marchese, R., Paccheti, C., Zagaglia, R., Logroscino, G., Defazio, G., Lamberti, P., Livrea, P., Hyperhomocysteine in levodopa-treated patients with Parkinson's disease dementia. Mov. Dis. 24:7 (2009), 1028–1033.
20. [20] Slawek, J., Roszmann, A., Robowski, P., Dubaniewicz, M., Sitek, E.J., Honczarenko, K., Gorzkowska, A., Budrewiczi, S., Mak, M., Gołąb-Janowskae, M., Koziorowska-Gawroni, E., Droździkg, M., Kurzawskig, M., Bandurskic, T., Białeckag, M., The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors. Neurodegener. Dis. 12 (2013), 1–12.
21. [21] Song, I.U., Kim, J.S., Park, I.S., Kim, Y.D., Cho, H.J., Chung, S.W., Lee, K.S., Clinical significance of homocysteine on dementia in Parkinson's disease. Arch. Gerontol. Geriatr. 57 (2013), 288–291.
22. [22] Bialecka, M., Kurzawski, M., Roszmann, A., Robowski, P., Sitek, E.J., Honczarenko, K., Gorzkowska, A., Budrewicz, S., Mak, M., Jarosz, M., Goła ̨b-Janowska, M., Koziorowska-Gawron, E., Droz ́dzik, M., Sławek, J., Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease. Pharmacogenetic Genom. 22:10 (2012), 716–724.
23. [23] Zoccolella, S., Lamberti, P., Lliceto, G., Diroma, C., Armenise, E., Defazio, G., Lamberti, S.V., Fraddosio, A., Mari, M.D., Livrea, P., Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin. Chem. Lab. Med. 43:10 (2005), 1107–1110.
24. [24] Gan, R., Zhang, Y.H., Nie, K., Wang, L., Correlation between cognitive dysfunction and plasma homocysteine level in patients with Parkinson's disease. Chin. J. Geriatr. Heart Brain Vessel Dis. 14:3 (2012), 231–232.
25. [25] Yu, J.M., Pan, X.P., Discussion the correlation of homocysteine levels with the Parkinson's disease and its cognitive impairment. MMJK 16 (2014), 23–25.
26. [26] Ju, X.C., Wang, W., Qu, Q.M., Da Rong Luo, G.G., Zhao, T.T., Song, W.F., Relationship between high homocysteine levels in serum and cognitive impairment of patients with Parkinson's disease. J. Chengdu Med. College 10:5 (2015), 525–527.
27. [27] Liu, Y., Analysis of correlation between plasma of homocysteine levels and cognitive impairment in elderly patients with Parkinson's disease. J. Brain Nerv. Dis. 23:5 (2015), 383–385.
28. [28] Niu, W.S., Plasma homocysteine changes and cognitive function of elderly with Parkinson's disease. Chin Pract Med. 11:March (8) (2016), 123–124.
29. [29] Xu, L.P., Study on the relation of plasma homocysteine with mild cognitive impairment in Parkinson's disease, Hunan, Xiangya School of Medicine. Cent. South Univ., 2013, 1–47.
30. [30] Cai, J.P., Li, G.Q., Hong, Q.L., Wei, X.L., Huang, D.X., Association between plasma homocysteine and cognitive dysfunction in patients with Parkinson's disease. J. Chin. Prescrip. Drug. 12:8 (2015), 3–5.
31. [31] Pan, N.F., Ye, M., Relationship between plasma homocysteine and Parkinson's disease with dementia. Jiangsu Med. J. 40:October (19) (2014), 2278–2280.
32. [32] Hu, X.W., Qin, S.M., Li, D., Hu, L.F., Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis. Acta Neurol. Scand. 128 (2013), 73–82.
33. [33] Religa, D., Czyzewski, K., Styczynska, M., Peplonska, B., Lokk, J., Chodakowska-Zebrowska, M., Stepien, K., Winblad, B., Barcikowska, M., Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci. Lett. 404:1–2 (2006), 56–60 (August 14).
34. [34] Muller, T., Muhlack, S., Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease. Parkinsonism Related Dis. 16:10 (2010), 688–689.
35. [35] Chango, A., Boisson, F., Barbe, F., Quilliot, D., Droesch, S., Pfister, M., Fillon-Emery, N., Lambert, D., Frémont, S., Rosenblatt, D.S., Nicolas, J.P., The effect of 677CT and 1298AC mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br. J. Nutr. 83:June (6) (2000), 593–596.
36. [36] Cacciapuoti, F., Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer's disease. J. Thromb Thrombolysis 36:3 (2013 Oct), 258–262.
37. [37] Seshardi, S., Beiser, A., Selhub, J., Rosenberg, I.H., D'Agostino, R.B., Wilson, P.W., Wolf, P.A., Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346:7 (2002), 476–483 (February 14).
38. [38] Camicioli, R.M., Bouchard, T.P., Somerville, M.J., Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients. Mov. Disord. 24 (2009), 176–182.
39. [39] Zhuo, J.M., Wang, H., Pratico, D., Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker or neither?. Trends Pharmacol. Sci. 32:September (9) (2011), 562–571.
40. [40] Hooshmand, B., Polvikoski, T., Kivipelto, M., Tanskanen, M., Myllykangas, L., Erkinjuntti, T., et al. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain: J. Neurol. 136:Pt 9 (2013), 2707–2716.
41. [41] den Heijer, T., Vermeer, S.E., Clarke, R., Oudkerk, M., Koudstaal, P.J., Hofman, A., et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain: J. Neurol. 126:1 (2003), 170–175.
42. [42] Aarsland, D., Zaccai, J., Brayne, C., A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Dis. 20:October (10) (2005), 1255–1263.
43. [43] Zoccolella, S., Lamberti, S.V., Iliceto, G., Santamato, A., Lamberti, P., Logroscino, G., Hyperhomocysteinemia in levodopa treated patients with Parkinson's disease: potential implications in cognitive dysfunction and dementia?. Curr. Med. Chem. 17:28 (2010), 3253–3261.
44. [44] Emre, M., Aarsland, D., Brown, R., Burn, D.J., Duyckaerts, C., Mizuno, Y., Broe, G.A., Cummings, J., Dickson, D.W., Gauthier, S., Goldman, J., Goetz, C., Korczyn, A., Lees, A., Levy, R., Litvan, I., McKeith, I., Olanow, W., Poewe, W., Quinn, N., Sampaio, C., Tolosa, E., Dubois, B., Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Dis. 22:12 (2007), 1689–1707 (September 15).
45. [45] Duan, W., Ladenheim, B., Cutler, R.G., Kruman, I.I., Cadet, J.L., Mattson, M.P., Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 80:January (1) (2002), 101–110.
46. [46] Reutens, S., Sachdev, P., Homocysteine in neuropsychiatric disorders of the elderly. Int. J. Geriatr. Psychiatry 17:September (9) (2002), 859–864.